Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HCC1806 | TNBC | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 0.0362 | uM | 7450.091 | 2.7673 | 4.3125 | 1.0419 | |
| Hs 578T | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.000219 | uM | 7861.018 | 2.3084 | 4.3604 | 0.8485 | |
| HCC1806 | TNBC | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 0.904 | uM | 7450.091 | 2.8027 | 4.3776 | 1.0419 | |
| MDA-MB-157 | TNBC | Basal B | Sirolimus | MTOR | MTOR | 0.00213 | uM | 7495.069 | 1.6549 | 4.3822 | 0.5089 | |
| LY2 | HR+ | Luminal | Purvalanol A | CDK1 | CDK | 1.33 | uM | 7477.067 | 1.9640 | 4.4065 | 0.6787 | |
| MDA-MB-134-VI | HR+ | Luminal | Doxorubicin | TOP2 | TOP | 0.0276 | uM | 7877.007 | 1.8289 | 4.4918 | 0.5977 | |
| HCC1806 | TNBC | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00723 | uM | 7450.091 | 2.8858 | 4.5306 | 1.0419 | |
| LY2 | HR+ | Luminal | ZM-447439 | AURK | AURK | 0.267 | uM | 10816.15 | 1.3786 | 4.7683 | 0.3031 | |
| SUM185PE | TNBC | Luminal | 5-DFUR | TYMS | TYMS | 8 | uM | 12269.143 | 1.3885 | 4.7897 | 0.3088 | |
| SUM185PE | TNBC | Luminal | Ibandronate | FDPS | 0.0192 | uM | 12269.143 | 1.3938 | 4.8625 | 0.3088 | ||
| LY2 | HR+ | Luminal | Glycyl-H-1152 | ROCK2 | 0.0107 | uM | 10816.15 | 1.3861 | 4.8724 | 0.3031 | ||
| Hs 578T | TNBC | Basal B | Trichostatin A | HDAC | HDAC | 0.064 | uM | 7472.065 | 2.9067 | 4.9213 | 0.9830 | |
| MDA-MB-157 | TNBC | Basal B | Sirolimus | MTOR | MTOR | 0.0000853 | uM | 7495.069 | 1.7513 | 5.0159 | 0.5089 | |
| SUM159PT | TNBC | Basal B | Z-Leu-Leu-Norvalinal | Proteasome | Proteasome | 0.000171 | uM | 14176.189 | 1.6080 | 5.0593 | 0.4285 | |
| SUM185PE | TNBC | Luminal | 5-DFUR | TYMS | TYMS | 0.064 | uM | 12269.143 | 1.4088 | 5.0690 | 0.3088 | |
| LY2 | HR+ | Luminal | Glycyl-H-1152 | ROCK2 | 0.0533 | uM | 10816.15 | 1.4003 | 5.0731 | 0.3031 | ||
| LY2 | HR+ | Luminal | Tozasertib | AURK/FLT3/ABL/JAK2 | AURK | 0.000427 | uM | 10816.15 | 1.4082 | 5.1867 | 0.3031 | |
| SUM185PE | TNBC | Luminal | Valproic acid | HDAC | HDAC | 4.8 | uM | 12269.143 | 1.4179 | 5.1973 | 0.3088 | |
| LY2 | HR+ | Luminal | GSK1838705A | IGF1R | RTK | 0.0384 | uM | 7477.071 | 1.8035 | 5.3252 | 0.5122 | |
| LY2 | HR+ | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 40 | uM | 7477.084 | 3.0073 | 5.3920 | 0.9476 | |
| LY2 | HR+ | Luminal | ZM-447439 | AURK | AURK | 0.000427 | uM | 10816.15 | 1.4618 | 5.9987 | 0.3031 | |
| HCC38 | TNBC | Basal B | Carboplatin | DNA cross-linker | DNA cross-linker | 0.00345 | uM | 10268.12 | 1.5129 | 6.0907 | 0.3272 | |
| LY2 | HR+ | Luminal | Glycyl-H-1152 | ROCK2 | 0.000427 | uM | 10816.15 | 1.4683 | 6.1020 | 0.3031 | ||
| SUM185PE | TNBC | Luminal | Ibandronate | FDPS | 0.00384 | uM | 12269.143 | 1.4815 | 6.1435 | 0.3088 | ||
| HCC38 | TNBC | Basal B | Carboplatin | DNA cross-linker | DNA cross-linker | 0.0862 | uM | 10268.12 | 1.5284 | 6.3141 | 0.3272 |